Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
PRISM BioLab Slips on Profit-Taking Despite Joint Presentation with Eisai on E7386 Preclinical Data◇
Notice of Nominees for Directors
Eisai Announces Appointment of Corporate Officers
FY 2025 (Ending March 31,2026) Third Quarter Financial Results Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Nine-Month Period Ended December 31, 2025
Eisai, Apr-Dec (Cumulative 3Q) Net Income Decreases by 8%, Exceeds Full-Year Plan
Revenue of LEQEMBI (Preliminary Basis)
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Six-Month Period Ended September 30, 2025
Eisai, Jul-Sep (2Q) Net Income Decreases by 9%
Financial Results for the Six-Month Period Ended September 30,2025 Reference Data
Revenue of LEQEMBI (Preliminary Basis)
Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.
FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
FY 2025 (Ending March 31,2026) First Quarter Financial Results Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2025
Eisai, Apr-Jun (1Q) Net Income Increases by 37%
Revenue of LEQEMBI (Preliminary Basis)
Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.
FY 2024 (Ended March 31,2025) Full Year Financial Results Reference Data